References

The future of the radiopharmaceutical sciences

10.1016/j.nucmedbio.2024.108907 · 2024 · External reference

10.1016/s1470-2045(19)30821-6

10.1016/s1470-2045(19)30821-6 · External reference

10.1016/s1470-2045(24)00030-5

10.1016/s1470-2045(24)00030-5 · External reference

Pilot experience of [161Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry

10.7150/thno.115831 · 2025 · External reference

10.1056/nejmoa1607427

10.1056/nejmoa1607427 · External reference

Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications

10.3390/pharmaceutics13010049 · 2020 · External reference

10.1056/nejmoa2107322

10.1056/nejmoa2107322 · External reference

Aspects and prospects of preclinical theranostic radiopharmaceutical development

10.7150/thno.100339 · 2024 · External reference

Production and radiochemistry of the in vivo PET generator 140Nd/140Pr as an imaging surrogate for f-block therapeutic radionuclides

10.1038/s41598-025-18929-4 · 2025 · External reference

Neodymium-140 DOTA-LM3: evaluation of an in vivo generator for PET with a non-internalizing vector

10.3389/fmed.2017.00098 · 2017 · External reference

10.1038/s41598-022-07147-x

10.1038/s41598-022-07147-x · External reference

Production of the 140Nd/140Pr radionuclide generator for biomedical studies

1999 · External reference

Twenty-five years with HER2 targeted therapy

10.21037/atm-23-153 · 2024 · External reference

[89Zr]trastuzumab: evaluation of radiation dosimetry, safety, and optimal imaging parameters in women with HER2-positive breast cancer

10.1007/s11307-016-0951-z · 2016 · External reference

Development of 52Mn labeled trastuzumab for extended time point pet imaging of HER2

10.1007/s11307-024-01948-4 · 2024 · External reference

Stability constants of the lanthanide(III)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetate complexes

10.1016/0020-1693(94)03964-x · 1994 · External reference

Implementing f-block metal ions in medicine: tuning the size selectivity of expanded macrocycles

10.1021/acs.inorgchem.9b01277 · 2019 · External reference

Activation cross sections of proton-induced reactions on praseodymium up to 30 MeV

10.1016/j.nimb.2021.10.006 · 2021 · External reference

Improved 140Nd production for the 140Nd/140Pr in vivo generator through target recycling and radiochemical optimization

10.1021/acsomega.6c03114 · 2026 · External reference

10.1002/anie.201709532

10.1002/anie.201709532 · External reference

Production and in vivo PET/CT imaging of the theranostic pair 132/135La

10.1038/s41598-019-47137-0 · 2019 · External reference

Construction of the bioconjugate py‐macrodipa‐PSMA and its in vivo investigations with large 132/135La3+ and small 47Sc3+ radiometal ions

10.1002/ejic.202300457 · 2023 · External reference

It’s a match: use of the radionuclide theranostic pair 133La/225Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies

10.1186/s41181-025-00354-7 · 2025 · External reference

10.2967/jnumed.121.262459

10.2967/jnumed.121.262459 · External reference

Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152Tb-DOTATOC

10.1039/c7dt01936j · 2017 · External reference

Production and purification of radiolabeling-ready 132/135La from the irradiation of metallic natBa targets with low energy protons

10.1016/j.nucmedbio.2025.108994 · 2025 · External reference

10.2967/jnumed.120.255794

10.2967/jnumed.120.255794 · External reference

Efficient production of the PET radionuclide 133La for theranostic purposes in targeted alpha therapy using the 134Ba(p,2n)133La reaction

10.3390/ph15101167 · 2022 · External reference

High yield cyclotron production of a novel 133/135La theranostic pair for nuclear medicine

10.1038/s41598-020-79198-x · 2020 · External reference

Establishing radiolanthanum chemistry for targeted nuclear medicine applications

10.1002/chem.201905202 · 2020 · External reference

Preclinical evaluation of [13xLa]La-FAP-2286 as a novel theranostic agent for tumors expressing fibroblast activation protein

10.1038/s41598-025-91716-3 · 2025 · External reference

10.2967/jnumed.122.265355

10.2967/jnumed.122.265355 · External reference

10.1016/j.nucmedbio.2022.04.007

10.1016/j.nucmedbio.2022.04.007 · External reference

A 140Nd/140Pr radionuclide generator based on physico-chemical transitions in 140Pr complexes after electron capture decay of 140Nd-DOTA

10.1524/ract.2007.95.6.319 · 2007 · External reference

Developing the 134Ce and 134La pair as companion positron emission tomography diagnostic isotopes for 225Ac and 227Th radiotherapeutics

10.1038/s41557-020-00598-7 · 2021 · External reference

Examination of the PET in vivo generator 134Ce as a theranostic match for 225Ac

10.1007/s00259-024-06811-w · 2024 · External reference

Macrocyclic receptor exhibiting unprecedented selectivity for light lanthanides

10.1021/ja808534w · 2009 · External reference

Macrocyclic ligands with an unprecedented size-selectivity pattern for the lanthanide ions

10.1021/jacs.0c05217 · 2020 · External reference

89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors

10.3390/ph5010079 · 2012 · External reference

10.2967/jnumed.108.060392

10.2967/jnumed.108.060392 · External reference

10.2967/jnumed.125.269741

10.2967/jnumed.125.269741 · External reference